Breaking Finance News

Biogen (NASDAQ:BIIB) target price bumped up to $270.00, issued a report today by UBS

Biogen (NASDAQ:BIIB) had its target price increased to $270.00 by UBS in a report issued 6/19/2017. The updated target suggests a potential upside of 0.07% from the company's previous close.

Having a price of $251.74, Biogen (NASDAQ:BIIB) traded 0.71% higher on the day. With the last close down 14.98% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. BIIB has recorded a 50-day average of $300.47 and a two hundred day average of $278.47. Trade Volume was down over the average, with 185,928 shares of BIIB changing hands under the typical 1,360,980

Recent Performance Chart


Biogen has PE ratio of 21.01 with a one year low of $244.28 and a one year high of $330.00 and has a total market value of $0.

A total of 19 equity analysts have released a ratings update on BIIB. Six equity analysts rating the company a strong buy, eight equity analysts rating the company a buy, nine equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $333.47.

Brief Synopsis About Biogen (NASDAQ:BIIB)

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.